Transparency requirements under the French Sunshine Act: life sciences companies in the dark?
The implementing decree giving full effect to the French ‘Sunshine Act’ requires life sciences companies to disclose specifically listed information regarding agreements with, and benefits as of €10 to, a wide range of healthcare actors. Awaiting the establishment of a single public website to be created for that purpose, the information must be published on the companies’ websites (or a website of a group of companies) and — when concerning healthcare professionals or students — the website of the relevant healthcare professionals’ order. The information must remain available for a period of five years.
Immediate action is required, in particular with regard to information on agreements and benefits involving healthcare professionals or students (or their respective associations). Such information, for the year of 2012, had to be submitted to the National Council of the respective orders by 1 June 2013; information related to the first calendar half of 2013 is due by 1 August 2013. Companies have a little more time to adjust their websites for purposes of the required disclosure as the publication deadline for the information on agreements and benefits entered into, or granted between, 1 January 2012 and 30 June 2013 is set at 1 October of this year.
Non-compliance with these transparency requirements may subject life sciences companies to a criminal fine of up to €225,000. The decree also contains further specifications related to the anti-gift statute, as implemented in Article L. 4113-6 of the Public Health Code (PHC), which are not further discussed in this e-alert…
If you are registered and logged in to the site, click on the link below to read the rest of the Allen & Overy briefing. If not, please register or sign in with your details below.
News from Allen & Overy
News from The Lawyer
Briefings from Allen & Overy
The Provincial Court of Madrid has upheld a hybrid dispute resolution clause. The judgment is the first one in Spain that recognises the validity of hybrid arbitration clauses.
There is no accepted formula for dealing with many of the issues that arise in negotiating a joint venture.
Analysis from The Lawyer
Advisers get stuck into the disentangling task, to unhitch troubled bank from group
Shell legal director Peter Rees is switching litigation control away from external counsel to a unified global team of in-housers